|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Karuturi M, VanderWalde N and Muss H:
Approach and management of breast cancer in the elderly. Clin
Geriatr Med. 32:133–153. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Savas P, Salgado R, Denkert C, Sotiriou C,
Darcy PK, Smyth MJ and Loi S: Clinical relevance of host immunity
in breast cancer: from TILs to the clinic. Nat Rev Clin Oncol. Dec
15–2015.doi: 10.1038. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sun Z, Shi Y, Shen Y, Cao L, Zhang W and
Guan X: Analysis of different HER-2 mutations in breast cancer
progression and drug resistance. J Cell Mol Med. 19:2691–2701.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kim DK, Kim DW, Kim SW, Kim DY, Lee CH and
Rhee CS: Ki67 antigen as a predictive factor for prognosis of
sinonasal mucosal melanoma. Clin Exp Otorhinolaryngol. 1:206–210.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Cuzick J, Dowsett M, Pineda S, Wale C,
Salter J, Quinn E, Zabaglo L, Mallon E, Green AR, Ellis IO, et al:
Prognostic value of a combined estrogen receptor, progesterone
receptor, Ki-67, and human epidermal growth factor receptor 2
immunohistochemical score and comparison with the Genomic Health
recurrence score in early breast cancer. J Clin Oncol.
29:4273–4278. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Krüger K, Stefansson IM, Collett K, Arnes
JB, Aas T and Akslen LA: Microvessel proliferation by co-expression
of endothelial nestin and Ki-67 is associated with a basal-like
phenotype and aggressive features in breast cancer. Breast.
22:282–288. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Goldhirsch A, Wood WC, Coates AS, Gelber
RD, Thürlimann B and Senn HJ: Panel members: Strategies for
subtypes - dealing with the diversity of breast cancer: Highlights
of the St. Gallen International Expert Consensus on the Primary
Therapy of Early Breast Cancer 2011. Ann Oncol. 22:1736–1747. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hou J, Wang P, Lin L, Liu X, Ma F, An H,
Wang Z and Cao X: MicroRNA-146a feedback inhibits RIG-I-dependent
Type I IFN production in macrophages by targeting TRAF6, IRAK1, and
IRAK2. J Immunol. 183:2150–2158. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Cintra JR, Teixeira MT, Diniz RW,
Gonçalves Junior H, Florentino TM, Freitas GF, Oliveira LR, Neves
MT, Pereira T and Guerra MR: Immunohistochemical profile and
clinical-pathological variables in breast cancer. Rev Assoc Med
Bras. 58:178–187. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Xiao ZS, Li Y, Guan YL and Li JG: GSTT1
polymorphism and breast cancer risk in the Chinese population: an
updated meta-analysis and review. Int J Clin Exp Med. 8:6650–6657.
2015.PubMed/NCBI
|
|
13
|
Hong W and Dong E: The past, present and
future of breast cancer research in China. Cancer Lett. 51:1–5.
2014. View Article : Google Scholar
|
|
14
|
Arjonen A, Kaukonen R, Mattila E, Rouhi P,
Högnäs G, Sihto H, Miller BW, Morton JP, Bucher E, Taimen P, et al:
Mutant p53-associated myosin-X upregulation promotes breast cancer
invasion and metastasis. J Clin Invest. 124:1069–1082. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Macpherson IR, Rainero E, Mitchell LE, van
den Berghe PV, Speirs C, Dozynkiewicz MA, Chaudhary S, Kalna G,
Edwards J, Timpson P, et al: CLIC3 controls recycling of late
endosomal MT1-MMP and dictates invasion and metastasis in breast
cancer. J Cell Sci. 127:3893–3901. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Beresford MJ, Wilson GD and Makris A:
Measuring proliferation in breast cancer: Practicalities and
applications. Breast Cancer Res. 8:2162006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Miller HC, Drymousis P, Flora R, Goldin R,
Spalding D and Frilling A: Role of Ki-67 proliferation index in the
assessment of patients with neuroendocrine neoplasias regarding the
stage of disease. World J Surg. 38:1353–1361. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Rademakers SE, Hoogsteen IJ, Rijken PF,
Terhaard CH, Doornaert PA, Langendijk JA, van den Ende P, van der
Kogel AJ, Bussink J and Kaanders JH: Prognostic value of the
proliferation marker Ki-67 in laryngeal carcinoma: results of the
accelerated radiotherapy with carbogen breathing and nicotinamide
phase III randomized trial. Head Neck. 37:171–176. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Warth A, Cortis J, Soltermann A, Meister
M, Budczies J, Stenzinger A, Goeppert B, Thomas M, Herth FJ,
Schirmacher P, et al: Tumour cell proliferation (Ki-67) in
non-small cell lung cancer: A critical reappraisal of its
prognostic role. Br J Cancer. 111:1222–1229. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Pollack A, DeSilvio M, Khor LY, Li R,
Al-Saleem TI, Hammond ME, Venkatesan V, Lawton CA, Roach M III,
Shipley WU, et al: Ki-67 staining is a strong predictor of distant
metastasis and mortality for men with prostate cancer treated with
radiotherapy plus androgen deprivation: Radiation Therapy Oncology
Group Trial 92-02. J Clin Oncol. 22:2133–2140. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Khor LY, Bae K, Paulus R, Al-Saleem T,
Hammond ME, Grignon DJ, Che M, Venkatesan V, Byhardt RW, Rotman M,
et al: MDM2 and Ki-67 predict for distant metastasis and mortality
in men treated with radiotherapy and androgen deprivation for
prostate cancer: RTOG 92-02. J Clin Oncol. 27:3177–3184. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Inwald EC, Klinkhammer-Schalke M,
Hofstädter F, Zeman F, Koller M, Gerstenhauer M and Ortmann O:
Ki-67 is a prognostic parameter in breast cancer patients: Results
of a large population-based cohort of a cancer registry. Breast
Cancer Res Treat. 139:539–552. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zheng Z, Li HZ and Li YQ: Prognostic
factors and associated models for metastatic renal cell carcinoma
treated with targeted therapy. Zhongguo Yi Xue Ke Xue Yuan Xue Bao.
36:450–453. 2014.(In Chinese). PubMed/NCBI
|
|
24
|
Pichu S, Krishnamoorthy S, Shishkov A,
Zhang B, McCue P and Ponnappa BC: Knockdown of Ki-67 by
dicer-substrate small interfering RNA sensitizes bladder cancer
cells to curcumin-induced tumor inhibition. PLoS One. 7:e485672012.
View Article : Google Scholar : PubMed/NCBI
|
